Category: Drug Delivery


Global Formulation Report 
Posted on Jul 24, 2015

  The July/August issue of Drug Development and Delivery has an extensive report on the business and science of formulation and drug delivery. The report is based on the data in the PharmaCircle database.  The report is divided into various “Top Ten” categories, such as Ten Notable Drug Delivery Technologies of 2014, Transactions, etc., etc. 

Small Molecule PEGylation: An Idea Ready For Prime Time 
Posted on Sep 17, 2014

At Lacerta Bio, we’re big believers in the therapeutic benefits of drug delivery in its many forms. Today, another drug delivery effort earned an FDA approval. In this case, it’s naloxegol from Nektar (and its partner, AstraZeneca). Naloxegol was approved for the treatment of opioid-induced constipation. Naloxegol is a highly interesting molecule because it consists of

Drug Delivery is Alive and Well 
Posted on Jan 23, 2013

The announcement of the Allergan acquisition of MAP Pharmaceuticals for nearly $1 billion (and the NuPathe approval) is a good reminder of the potential value (both clinical and financial) of reformulation and drug delivery approaches to product development. Now there no question that new pharmacologies are needed in just about all therapeutic categories. Unmet needs continue to persist

Predictions for 2013 
Posted on Jan 02, 2013

Happy New Year! For many companies, 2012 was a challenging year. How will 2013 play out? Here are a few ideas we’ve discussed internally as we look forward to 2013: Innovation versus Revenue – Companies (and their investors) talk a lot about innovation. And indeed, innovation is important. However, what companies really really want is

Repositioned Drugs Surpass New Brands 
Posted on Oct 26, 2012

There are some very interesting data published yesterday on FDA approval statistics: It was in 1984 when FDA first added the 505(b)(2) pathway for drug approval, a hybrid between the accelerated pathway for generic drug applications, and the standard de novo NDA pathway for proprietary drugs. But in the past 6 years, approvals received through

Need for new drug delivery technologies is greater than ever 
Posted on May 09, 2012

So said Shams Ruston from Labopharm at last week’s Interphex conference in New York. We happen to agree. In fact, there are two ways to look at this. From the branded side, drug delivery can help extend the patent life of existing assets…a far less risky and less costly approach than trying to in-license the

Flamel – Eclat and NicOx – Altacor: What can we learn? 
Posted on Mar 21, 2012

The past seven days have brought us two very interesting transactions. First, on March 14, Lyon-based Flamel announced their acquisition of St. Louis-based Eclat Pharmaceuticals. The press release contains a number of interesting nuggets, but this one caught our eye: Mr. Willard concluded, “We expect that the combination of Mike’s [Anderson] drug development and regulatory

Reformulating Injectables for Oral Delivery 
Posted on Nov 03, 2011

Lacerta Bio was pleased to take part in a terrific overview of technologies for oral delivery of peptides and proteins: The oral delivery of biopharmaceuticals is highly desirable because it would provide ease of administration and improve patient compliance. But oral administration remains an elusive goal in biopharmaceutical drug delivery. To date, major obstacles have

AAPS: Impressions and Observations 
Posted on Oct 27, 2011

Lacerta Bio spent the week at the AAPS ( American Association of Pharmaceutical Scientists ) annual conference . Over 8,000 pharmaceutical scientists, service providers, and others came to AAPS in DC to talk pharmaceutical science, especially formulation development, translational research, pharmacokinetics, and manufacturing. As the name suggests, AAPS is a science-driven conference. Thus, the tone

Looking for a job in pharma? Good luck 
Posted on Jul 14, 2011

Today, KPMG is reporting results from a survey of pharmaceutical executives. In this survey, respondents said they will increase their acquisition activity in the coming year in order to gain new therapies and new customers. In the KPMG survey, 83 percent of executives said it is likely their company will be involved in a merger

BioTrinity Panel Discussions 
Posted on Apr 21, 2011

We regret that we were unable to attend the panel discussions at BioTrinity last week. However, an excellent summary was posted on the PharmaPhorum web site. Of note: 1. Investment syndication is becoming increasingly important. 2. Big pharma/Big biotech are looking at earlier-stage assets, perhaps more so than ever. Even early-stage technologies coming out of

Drug Development and Delivery: What’s in a name? 
Posted on Dec 21, 2010

Our good friends at Drug Delivery Technology have, as of January, changed the name of their publication to Drug Development and Delivery. Why is this significant? We think that drug delivery and drug development will become increasingly synonymous. Indeed, we’ve blogged in the past about some of the areas where traditional drug delivery techniques can

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.